drugset

drugset / Trial / NCT02137889

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

NCT02137889 ↗

Phase 1 Terminated 3 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and preliminary efficacy of escalating doses of VAY736 in relapsed or refractory CLL patients.

Timeline

Start: 2012-07
Primary completion: 2012-11
Completion: 2012-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ianalumab	Monoclonal antibody	—	Intravenous

Indications